Simple Summary FGFR inhibitors evolved as therapeutic options in cholangiocarcinoma
and urothelial malignancies. Given the implications of FGFR pathway in various …

Chronic kidney disease (CKD) is a complex and multifactorial disease, and one of the most
prevalent worldwide. Chronic kidney disease–mineral bone disorders (CKD–MBD) with …

Background Phosphate binders are used to reduce positive phosphate balance and to lower
serum phosphate levels for people with chronic kidney disease (CKD) with the aim to …

Despite the availability of global and regional guidelines to curtail the adverse clinical
outcomes associated with chronic kidney disease–mineral and bone disorder (CKD-MBD) …

Hyperphosphatemia is a common complication in patients with chronic kidney disease
(CKD), particularly in those requiring renal replacement therapy. The importance of …

Background Guidelines preferentially recommend noncalcium phosphate binders in adults
with chronic kidney disease (CKD). We compare and rank phosphate-binder strategies for …

The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline
Update for the Diagnosis, Evaluation, Prevention, and Treatment of chronic kidney disease …

Fibroblast growth factor receptor (FGFR) inhibitors have shown promising results in terms of
objective response rates in phase I/II trials in various malignancies that harbor FGFR genetic …

Hyperphosphatemia is common among patients with CKD stage 5D and is associated with
morbidity and mortality. Current guidelines recommend lowering serum phosphate …

Cardiovascular (CV) disease (CVD) accounts for> 50% of deaths with known causes in
patients on dialysis. Elevated serum phosphorus levels are an important nontraditional risk …